应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
APL Atlas Pipeline Partners L.P.
交易中 05-20 11:52:36 EDT
0.0000
+0.0000
--
最高
0.0000
最低
0.0000
成交量
0.00
今开
0.0000
昨收
0.0000
日振幅
0.00%
总市值
0.00
流通市值
0.00
总股本
0.00
成交额
0.00
换手率
--
流通股本
0.00
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
直击调研 | 亚虹医药(688176.SH):APL-1202已于2022年12月完成II期临床首例受试者入组
智通财经 · 2023-02-01
直击调研 | 亚虹医药(688176.SH):APL-1202已于2022年12月完成II期临床首例受试者入组
亚虹医药(688176.SH):APL-1202口服联合替雷利珠单抗新辅助治疗肌层浸润性膀胱癌(MIBC)完成II期临床首例受试者入组
智通财经 · 2022-12-12
亚虹医药(688176.SH):APL-1202口服联合替雷利珠单抗新辅助治疗肌层浸润性膀胱癌(MIBC)完成II期临床首例受试者入组
NASA行星防御背后:撞了颗直径160米的小行星,耗7年21亿元
澎湃新闻 · 2022-09-29
NASA行星防御背后:撞了颗直径160米的小行星,耗7年21亿元
公司概况
公司名称:
Atlas Pipeline Partners L.P.
所属市场:
NYSE
上市日期:
--
主营业务:
发行价格:
--
{"stockData":{"symbol":"APL","market":"US","secType":"STK","nameCN":"Atlas Pipeline Partners L.P.","latestPrice":0,"timestamp":0,"preClose":0,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"05-20 11:52:36 EDT","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1779307200000},"marketStatusCode":2,"adr":0,"exchange":"NYSE","adjPreClose":0,"volumeRatio":0},"requestUrl":"/m/hq/s/APL/wiki","defaultTab":"wiki","newsList":[{"id":"2308070888","title":"直击调研 | 亚虹医药(688176.SH):APL-1202已于2022年12月完成II期临床首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2308070888","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2308070888?lang=zh_cn&edition=full","pubTime":"2023-02-01 11:51","pubTimestamp":1675223481,"startTime":"0","endTime":"0","summary":"APL-1202一线治疗未经治疗的中危NMIBC在持续入组受试者。亚虹医药表示,APL-1202口服联合替雷利珠单抗新辅助治疗肌层浸润性膀胱癌已于2022年12月完成II期临床首例受试者入组。此外,APL-1706于2022年3月获中国国家药品监督管理局药品审评中心批准,纳入药品临床真实世界数据应用试点。营销方面,亚虹医药称,根据海南省“先行先试”的相关规定,继APL-1706落地博鳌后,公司一次性膀胱软镜在2022年8月于海南省人民医院乐城院区完成首次使用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/869571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["APL","688176","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2290202286","title":"亚虹医药(688176.SH):APL-1202口服联合替雷利珠单抗新辅助治疗肌层浸润性膀胱癌(MIBC)完成II期临床首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2290202286","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2290202286?lang=zh_cn&edition=full","pubTime":"2022-12-12 17:20","pubTimestamp":1670836845,"startTime":"0","endTime":"0","summary":"智通财经APP讯,亚虹医药(688176.SH)公告,公司开展的APL-1202口服联合替雷利珠单抗新辅助治疗肌层浸润性膀胱癌(MIBC)临床试验,于近日完成II期临床试验首例受试者入组。据悉,APL-1202(商品名唯施可®)是一款口服的可逆性MetAP2抑制剂,具有抗血管生成、抗肿瘤活性及调节肿瘤免疫微环境的作用。临床前研究显示,APL1202与PD-1单抗联合用药在膀胱癌药效学模型上显示出协同作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/845797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688176","BK0239","APL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2271753099","title":"NASA行星防御背后:撞了颗直径160米的小行星,耗7年21亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2271753099","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2271753099?lang=zh_cn&edition=full","pubTime":"2022-09-29 05:57","pubTimestamp":1664402220,"startTime":"0","endTime":"0","summary":"当地时间9月26日,美国国家航空航天局“双小行星重定向测试”航天器成功撞击一颗名为迪莫弗斯的近地小行星。这是世界上首次进行旨在防御地球免遭小行星撞击威胁的任务。 据美国国家航空航天局电视台 9月27日报道,位于马里兰州劳雷尔的约翰斯·霍普金斯大学应用物理实验室的任务控制中心于美东时间27日19点14分宣布,在太空中飞行10个月后,NASA的DART航天器成功撞击了小行星迪莫弗斯,这是NASA首次尝试在太空中改变小行星运动轨道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/usstock/c/2022-09-29/doc-imqmmtha9149607.shtml?finpagefr=p_115","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2022-09-29/doc-imqmmtha9149607.shtml?finpagefr=p_115","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["APL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://","compareEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.0691},{"period":"6month","weight":0.1244},{"period":"1year","weight":0.2335},{"period":"ytd","weight":0.076}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"exchange":"NYSE","name":"Atlas Pipeline Partners L.P.","nameEN":"Atlas Pipeline Partners, L.P."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Atlas Pipeline Partners L.P.(APL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Atlas Pipeline Partners L.P.(APL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Atlas Pipeline Partners L.P.,APL,Atlas Pipeline Partners L.P.股票,Atlas Pipeline Partners L.P.股票老虎,Atlas Pipeline Partners L.P.股票老虎国际,Atlas Pipeline Partners L.P.行情,Atlas Pipeline Partners L.P.股票行情,Atlas Pipeline Partners L.P.股价,Atlas Pipeline Partners L.P.股市,Atlas Pipeline Partners L.P.股票价格,Atlas Pipeline Partners L.P.股票交易,Atlas Pipeline Partners L.P.股票购买,Atlas Pipeline Partners L.P.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Atlas Pipeline Partners L.P.(APL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Atlas Pipeline Partners L.P.(APL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}